Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

Core Insights - Regeneron Pharmaceuticals, Inc. will report its fourth quarter and full year 2025 financial and operating results on January 30, 2026, before U.S. financial markets open [1] - A conference call and webcast will be held at 8:30 AM Eastern Time on the same day [1] Company Overview - Regeneron is a leading biotechnology company focused on inventing, developing, and commercializing life-transforming medicines for serious diseases [3] - The company is founded and led by physician-scientists, emphasizing its ability to translate scientific research into approved treatments and product candidates [3] - Regeneron's medicines and pipeline target various conditions, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases [3] Technological Advancements - Regeneron utilizes proprietary technologies, such as VelociSuite, to produce optimized fully human antibodies and new classes of bispecific antibodies [4] - The company is advancing drug development through data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms [4] - These innovations enable Regeneron to identify new targets and approaches for potentially treating or curing diseases [4]